Loading the section…
The price of BridgeBio Pharma, Inc. (BBIO) on October 9, 2026 is 65.35 USD, +0.48% on the day. Over 52 weeks the stock traded between 52.75 USD and 93.42 USD; the price now sits 31% of the way up that range. Over the past year the price changed by +18.17%. Market capitalization is 12.79 billion USD, rank 21 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 4 November 2026 · Earnings calendar
Change over the period shown (line colour): +16.78 %
BridgeBio Pharma, Inc. trades on Nasdaq under the ticker BBIO. The company belongs to the Health care sector. The trading history on this page starts on 27 June 2019.
Over the past 52 weeks BBIO has traded between 52.75 $ and 93.42 $. As of 9 October 2026 the price stood 30.98 % of the way from the 52-week low to the high.
Over one year BBIO shares rose 18.17 %; over six months they fell 12.39 %. Volatility over 90 days is 38.72 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 22.1, above the sector median of 4.0. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 65.04 | 65.94 | 64.34 | 65.35 | 2M |
| 8 October 2026 | 66.39 | 66.41 | 63.70 | 65.04 | 3M |
| 7 October 2026 | 66.78 | 67.59 | 66.15 | 66.50 | 2M |
| 6 October 2026 | 67.75 | 68.12 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
BridgeBio develops drugs for diseases with a known genetic cause.
The approach differs in how targets are chosen: the company takes on only conditions where the faulty gene is identified — the drug's mechanism is then understood in advance, and the probability of success is above the industry average. Programmes are run through separate subsidiaries with their own funding.
The lead drug stabilises the protein that deposits in heart muscle in hereditary amyloidosis — a condition diagnosed increasingly often as the relevant imaging spreads. The market here is large and already occupied by a competitor, so the outcome turns not only on efficacy but on convenience of dosing. The company pays no dividend.
Address:3160 PORTER DR. SUITE 250, PALO ALTO, CA, 94304, US
BridgeBio Pharma, Inc. reported revenue of 580M $ and a net loss of 722M $ over the last four quarters. Net margin is −124.41 %. Revenue changed by +355.17 % year over year. Earnings per share are −3.74 $. Market capitalisation is 12.8B $.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 65.71 |
| 66.96 |
| 4M |
| 5 October 2026 | 67.40 | 68.08 | 65.46 | 66.14 | 2M |
| 2 October 2026 | 67.10 | 68.68 | 66.23 | 67.25 | 3M |
| 1 October 2026 | 65.72 | 67.26 | 65.16 | 66.91 | 4M |
| 30 September 2026 | 66.14 | 67.32 | 65.61 | 65.80 | 3M |
| 29 September 2026 | 66.38 | 67.16 | 65.82 | 65.97 | 4M |
| 28 September 2026 | 65.07 | 67.34 | 64.36 | 66.61 | 3M |
| 25 September 2026 | 66.50 | 67.07 | 64.84 | 65.57 | 2M |
| 24 September 2026 | 65.85 | 67.30 | 65.33 | 66.28 | 4M |
| 23 September 2026 | 69.23 | 70.00 | 64.90 | 65.71 | 4M |
| 22 September 2026 | 66.90 | 69.77 | 66.61 | 69.23 | 4M |
| 21 September 2026 | 67.01 | 67.33 | 65.78 | 66.58 | 3M |
| 18 September 2026 | 67.39 | 67.56 | 66.10 | 66.61 | 4M |
| 17 September 2026 | 69.72 | 69.99 | 66.93 | 67.31 | 2M |
| 16 September 2026 | 68.52 | 69.46 | 67.11 | 68.30 | 5M |
| 15 September 2026 | 72.26 | 72.41 | 66.96 | 68.39 | 4M |
| 14 September 2026 | 72.55 | 73.67 | 72.17 | 72.38 | 2M |